Answers are grounded in this paper and cite their sources.
Cross-sectional assessment reveals shifting characteristics of dupilumab-treated patients across pediatric populations, indicating channeling bias.
Selectively prescribing new medications to patients with severe disease can lead to channeling bias in observational studies. Potential for channeling upon label extension has not been described. The objective of this study was to describe dupilumab-treated patients with moderate-to-severe atopic dermatitis (AD) at initial United States Food and Drug Administration (FDA) approval for adults (March 2017) and at label extensions to adolescents (March 2019), children (May 2020), and young children (June 2022). A cross-sectional study was conducted using Optum’s de-identified Clinformatics® Data Mart Database to describe baseline characteristics of patients with AD in the US who initiated dupilumab within 6 months of FDA approval or label extension. Dupilumab-treated patients with AD at initial approval, versus the most recent label update, had a higher prevalence of comorbid Type 2 inflammatory diseases (e.g., asthma: 33% versus 22%), a larger proportion of prior systemic immunosuppressant use (31% versus 5%), and more frequent dermatologist visits in the previous year (mean 6.1 versus 3.1 visits). Newly licensed adolescents and children had a greater burden of atopic comorbidities and a different pattern of prior AD treatment than adults. Patients initiating dupilumab in March 2017 had markers of high disease burden, consistent with channeling. As the label extended, the population shifted toward the indicated moderate-to-severe phenotype. Channeling trends were difficult to assess given the well-established differences in comorbidities and treatment patterns in pediatric AD. Newly approved medications are likely to be selectively prescribed to patients with severe or poorly controlled disease, which can lead to “channeling bias” in observational studies. The United States Food and Drug Administration (FDA) initially approved dupilumab in March 2017 for the treatment of moderate-to-severe atopic dermatitis (AD, or “eczema”) in adults. The licensed AD population has since been expanded to include adolescents ≥ 12 years (as of March 2019), children 6–11 years (as of May 2020), and young children 6 months–5 years (as of June 2022). We examined characteristics of real-world patients with AD who initiated dupilumab within the 6-month period following initial FDA approval or label extension. Extension of dupilumab’s atopic dermatitis indication from adult to pediatric patients represents an evolution of the treated population. Patients treated with dupilumab in March 2017 had markers of a high disease burden, consistent with channeling of the new therapy as expected. As the label has extended, the population appears to have shifted toward the indicated moderate-to-severe phenotype. Time trends in channeling were difficult to assess given the different profile of baseline comorbidities and disease management strategies in dupilumab-treated patients over time.
No takes yet. Share an insight, caveat, or question.
Barberio et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: